Stockreport

Spyre: 'Strong Buy' As UC Program Moves Along And Q3 2026 RA Data Looms [Seeking Alpha]

Spyre Therapeutics, Inc.  (SYRE) 
PDF SPY001 demonstrated a half-life 4x greater than ENTYVIO, supporting quarterly or twice-yearly dosing for ulcerative colitis in the ongoing phase 2 SKYLINE trial. Acce [Read more]